丹红注射液治疗糖尿病肾病的临床效果及对血小板CD62p、PAC-1表达的影响

Clinical effect of Danhong Injection in the treatment of diabetic nephropathy and its influence on the expression of platelet CD62p,PAC-1

目的探讨丹红注射液治疗糖尿病肾病的临床效果及对血小板CD62p、PAC-1表达的影响。方法选取2014年12月～2015年12月河北北方学院附属第一医院收治的糖尿病肾病患者95例。将其随机分为观察组（50例）和对照组（45例）。对照组给予常规降糖、降压、降脂药物治疗，观察组在此基础上加用丹红注射液治疗，治疗2周，观察两组治疗前后血脂、肾功能相关指标，并检测血小板CD62p、PAC-1的表达。结果观察组总有效率为90．0％（45／50），对照组总有效率为64．4％（29／45），差异有高度统计学意义（x^2=6．905，P〈0．01）。两组治疗前血脂、尿蛋白排泄率（UAER）、尿素氮（BUN）、肌酐（SCr）、CD62p、PAC-1比较差异无统计学意义（P〉0．05）。对照组治疗前后总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL～C）和低密度脂蛋白胆固醇（LDL—C）比较差异无统计学意义（P〉0．05），观察组治疗后TC、TG、LDL—C明显下降，HDL—C明显升高，且与对照组治疗后比较差异有统计学意义（P〈0．05）。两组治疗后UAER、BUN和SCr均较治疗前明显改善，但观察组下降更显著，差异有统计学意义（P〈0．05）。观察组治疗后血小板CD62p、PAC-1阳性表达率明显低于治疗前及对照组治疗后（P〈o．05），而对照组治疗前后比较差异无统计学意义（P〉o．05）。结论丹红注射液可明显抑制糖尿病。肾病患者CD62p、PAC-1的表达，减少尿蛋白，降低血脂，改善肾功能。

Objective To investigate the clinical effect of Danhong Injection in the treatment of diabetic nephropathy and its influence on the expression of platelet CD62p, PAC-1. Methods Ninety five cases with diabetic nephropathy admitted to the First Affiliated Hospital of Hebei North University from December 2014 to December 2015 were select- ed and randomly divided into the observation group （50 cases） and the control group （45 cases）. The patients in the control group were treated by conventional hypoglycemic, hypotensive and lipid-lowering drugs, while the patients in the observation group were treated by Danhong Injection on the basis of conventional therapy for 2 weeks. The blood lipid, renal function indexes of the two groups before and after treatment were observed, and the expression of platelet CD62P and PAC-1 were detected. Results The total effective rate of the observation group was 90% （45/50）, the total effective rate of the controlk group was 64.4% （29/45）, and the difference was highly statistically significant （~2=6.905, P 〈 0.01）. There were no significant differences in blood lipid, urinary protein excretion rate （UAER）, serum creatinine （SCr）, CD62p, PAC-1 values between the two groups before treatment （P 〉 0.05）. There were no significant differences of total cholesterol tiC）, triacylglycerol （TG）, high density lipoprotein cholesterol （HDL-C） and low density lipoprotein cholesterin （LDL-C） before and after treatment in the control zrouo （P 〉 0.05）. After treatment. TC. TG and LDL-C in the observation group were decreased significantly, HDL-C was increased significantly, and the changes in the observation group were more obvious than those in the control group （P 〈 0.05）. UAER, BUN and SCr of the two groups after treatment were improved more sig- nificantly than those before treatment, while the observation group was decreased more significantly than those of control group, the differences were statistically significant （P 〈 0.05）. The positive rate of CD62p and PAC-1 in the observation group after treatment were significantly lower than those before treatment and those of control group after treatment （P 〈 0.05）, while those in the control group had no significant differences before and after treatment （P 〉 0.05）. Conclusion Danhong Injection can significantly inhibit the expression of CD62p and PAC-1 in patients with diabetic nephropathy, reduce urinary protein, lower blood lipid, and improve renal function.